Please assess the completion status of the following clinical trial:

Trial Title: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-65 years of age;~* HBeAg negative chronic hepatitis B;~* treated with lamivudine for \>=6 months;~* demonstrated lamivudine resistance;~* compensated liver disease.~Exclusion Criteria:~* severe hepatic dysfunction;~* previous treatment with antivirals other than lamivudine;~* immunosuppressant treatment in past 6 months;~* co-infection with hepatitis A, C, or D virus or human immunodeficiency virus;~* medical condition associated with chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).